Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease
Shots:
- The study evaluates Viatris’ Hulio & Sandoz’s Hyrimoz in 34 patients with CD and 16 with UC
- The results showed that adalimumab biosimilars, Hulio & Hyrimoz were found to be safe & effective for IBD. In CD & UC patients, 73.5% & 18.8% patients achieved remission, 11.8% & 43.8% had PR after 12wks., 11.8% & 25% had no response, and 1 & 2 discontinued therapy due to allergic reaction. Median CDAI & MSS value prior to therapy was 216.0 & 8.0 which decreased to 110.0 & 4.0 after 12wks. of treatment
- The results were published in Plos One. Adalimumab biosimilars were less effective than an infliximab biosimilar while patients treated with infliximab biosimilar Inflectra achieved remission (50% & 40.9%) after 14wk. with PR in 50.0% & 54.5% in the CD & UC
Ref: AJMC | Image: Viatris
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
